wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 201 - 250 of 286.

Medicine/Pharmacology - Physics/Materials Science
28.09.2016
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo   People with episodic migraine experience up to 14 migraine days each month and lose a substantial part of their lives to this debilitating disease   AMG 334 is being co-developed by Novartis and Amgen Basel, September 28, 2016 - Novartis today announc
Social Sciences
28.09.2016
Breaking down the barriers in our minds
Breaking down the barriers in our minds
What role does technology play in equality for people with disabilities? Experts and scientists have been discussing this question in the run-up to the world's first Cybathlon at ETH Zurich.
Astronomy - Event
27.09.2016
Rosetta, ESA’s historic mission, bids farewell after rendez-vous with comet Chury
Bern, 27.09.2016 - Rosetta is set to complete its mission in a controlled descent to the surface of its comet 67P/Churyumov-Gerasimenko on 30 September 2016.
Medicine/Pharmacology - Event
27.09.2016
Nutritionist Professor Johan Auwerx wins the 2016 Marcel Benoist Prize
Bern, 27.09.2016 - Johan Auwerx, Professor at the ETH Lausanne (EPFL), has been awarded this year's Marcel Benoist Prize for his work on mitochondria and their role in the metabolism.
Physics/Materials Science
26.09.2016
SwissFEL in the home stretch: The first electrons are here
SwissFEL in the home stretch: The first electrons are here
SwissFEL building, 24 August 2016: In the control room above the beam tunnel of the free electron X-ray laser SwissFEL, the atmosphere is intense and focussed.
Medicine/Pharmacology
26.09.2016
Broadly neutralizing HIV antibodies pave the way for vaccine
Broadly neutralizing HIV antibodies pave the way for vaccine
Prof. Alexandra Trkola, PhD Institute of Medical Virology University of Zurich Phone +41 44 634 53 80 E-mail Website Prof. Huldrych Günthard, MD Department of Infectious Diseases and Hospital
Physics/Materials Science
26.09.2016
3D-nanoprinting to turbocharge microscopes
3D-nanoprinting to turbocharge microscopes
26.09.16 - EPFL researchers have printed nanometric-scale sensors capable of improving the performance of atomic force microscopes. Tiny sensors made through nanoscale 3D printing may be the basis for the next generation of atomic force microscopes. These nanosensors can enhance the microscopes? sensitivity and detection speed by miniaturizing their detection component up to 100 times.
Physics/Materials Science - Chemistry
26.09.2016
Ultrafast processes in the blink of an eye
Ultrafast processes in the blink of an eye
Ultrafast processes beyond the human imagination occur in nature, but basic research has been able to measure and explore them only since the turn of the millennium.
Microtechnics/Electroengineering - Mechanical Engineering/Mechanics
25.09.2016
Learn how to walk
Learn how to walk
At first glance, exoskeletons conjure up images of futuristic robots from science fiction films. But the exoskeleton from the ETH team VariLeg is a real-life aid that could allow people with paraplegia to walk again.
Life Sciences
24.09.2016
Polybahn Pitch with Elsbeth Stern
Elsbeth Stern, Professor for Research on Learning and Instruction, explains in a Polybahn Pitch why physics is a difficult school subject and why it may be worth familiarising children with its basic concepts at an early age.
Medicine/Pharmacology - Life Sciences
23.09.2016
Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions
Ilaris (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease   These three simultaneous approvals conducted under FDA Priority Revie
Administration/Government - Medicine/Pharmacology
23.09.2016
Matthias Egger is the new president of the National Research Council of the SNSF
Matthias Egger is the new president of the National Research Council of the SNSF
Matthias Egger, internationally renowned epidemiologist and public health expert, will be the new president of the National Research Council of the SNSF as of 2017.
Medicine/Pharmacology - Life Sciences
23.09.2016
Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia in untreated adult ALK+ NSCLC patients
In a Phase III clinical study, Zykadia extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance    Novartis is moving forward with global regulatory su
Business/Economics - Administration/Government
23.09.2016
Astronomy - Event
23.09.2016
SwissCube: seven years in space and still active
SwissCube: seven years in space and still active
23.09.16 - The little Swiss satellite was launched on 23 September 2009 and continues to send back regular reports.
Medicine/Pharmacology - Administration/Government
22.09.2016
No proper treatment without sound diagnostic
A long-term partnership managed to reform radiology services in Egypt and to ensure the access of Egyptian citizens to save and performing imaging diagnostics.
Physics/Materials Science - Environment/Sustainable Development
22.09.2016
Renewable energy: Experimental platform ESI is starting up
Renewable energy: Experimental platform ESI is starting up
This fall, the time has come: The Energy System Integration Platform at the Paul Scherrer Institute PSI goes into operation.
Medicine/Pharmacology - Business/Economics
22.09.2016
Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs
Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites   KAF156, currently in phase IIb, is the first compound from a novel class of antimalarials known as imidazolopiperazines   Antimalarials with new mechanisms of action are urgently needed to tackle emerging parasite resistance to current therapies; Novartis
Physics/Materials Science - Chemistry
21.09.2016
Artificial Intelligence Helps in the Discovery of New Materials
Artificial Intelligence Helps in the Discovery of New Materials
With the help of artificial intelligence, chemists from the University of Basel in Switzerland have computed the characteristics of about two million crystals made up of four chemical elements. The researchers were able to identify 90 previously unknown thermodynamically stable crystals that can be regarded as new materials.
Administration/Government
21.09.2016
Stable on top level
Stable on top level
The university ranking list season draws to a close with the release of the THE Ranking. ETH Zurich has maintained its ninth place from last year.
Medicine/Pharmacology - Business/Economics
19.09.2016
Medicine/Pharmacology - Administration/Government
19.09.2016
Important new analysis shows that Novartis’ Entresto is associated with higher relative health-related quality of life scores among HFrEF patients
Important new analysis shows that Novartis' Entresto is associated with higher relative health-related quality of life scores among HFrEF patients New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores compared to those taking ACE inhibitor enalapril   In the overall study population, declines in HRQL scores we
Medicine/Pharmacology - Life Sciences
17.09.2016
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placebo in people with secondary progressive multiple sclerosis (SPMS)   SPMS is a progressive and highly disabling form of MS, and remains an area of significant unmet medical need   Novartis continues to build on its experience and expertise in MS to advance care for people with the condi
Medicine/Pharmacology - Life Sciences
16.09.2016
New Novartis data presented at ECTRIMS show benefit of Gilenya on patient disability progression at 10 years
ACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya (fingolimod) had significantly lower disability progression compared to those whose treatment was interrupted   Fewer patients who stayed on Gilenya therapy for eight to 10 years had developed secondary progressive MS compared to those who discontinued it   Almost 60% of patients enrolled in ACROSS remained on Gilenya treatment a
Event - Interdisciplinary/All Categories
16.09.2016
Letting ideas flow
Letting ideas flow
Water was the focus of ETH Week 2016. For the second edition of this week-long event, ETH Zurich called on bachelor's and master's students from all departments to approach a subject creatively and develop collective solutions.
Medicine/Pharmacology
15.09.2016
Novartis Foundation showcases progress in leprosy elimination programs at 19th International Leprosy Congress
Emerging evidence from first 18 months of LPEP program demonstrates operational feasibility integrating single-dose rifampicin into routine control programs in 6 countries   Retrospective tracing of former leprosy patients in Cambodia initiates phase 2 to accelerate diagnosis   Accuracy of first mobile phone-facilitated leprosy detection system to help identify patients in remote areas of the Philippines leads to recommendation for field use   C
Medicine/Pharmacology - Business/Economics
15.09.2016
Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine days compared to placebo   Chronic migraine is the most disabling form of the disease, and is associated with substantial personal pain and disability, and financial cost to society ,   AMG 334 is being co-developed by Novartis and Amgen for the preventi
Medicine/Pharmacology - Earth Sciences
14.09.2016
University of Zurich launches initiative for the Digital Society
University of Zurich launches initiative for the Digital Society
Buzzwords like Industry 4.0 or Big Data and the massive spread of digital technology, such as smartphones, apps or vehicles with state-of-the-art computers, all show one thing: Thanks to digitization, our society, our world of work and our free time are in the throes of a fundamental transformation.
Business/Economics - Administration/Government
14.09.2016
New funding programme to serve as launch pad for Swiss start-ups
Bern, 14.09.2016 - This autumn, the European Space Agency (ESA) and the State Secretariat for Education, Research and Education (SERI) will open an ESA Business Incubation Centre (ESA BIC) in Switzerland.
Chemistry - Physics/Materials Science
13.09.2016
On-Surface Chemistry Leads to Novel Products
On-Surface Chemistry Leads to Novel Products
On-surface chemical reactions can lead to novel chemical compounds not yet synthesized by solution chemistry. The first-step, second-step, and third-step products can be analyzed in detail using a high-resolution atomic force microscope, as demonstrated in Nature by scientists from the Swiss Nanoscience Institute and the Department of Physics at Basel University and their colleagues from Japan and Finland.
Mathematics - Philosophy
10.09.2016
Are there decisive answers to undecidable questions?
Unsolvable problems, the nature of the infinite and the question of whether and how mathematics can be definitively substantiated - these issues are the focus of the Bernays Lectures 2016. The speaker for this year's honorary lectures at ETH Zurich is W. Hugh Woodin, Professor of Philosophy and Mathematics at Harvard University.
Medicine/Pharmacology
09.09.2016
Child Stimulation Intervention Fosters Early Child Development in Rural Peru
Children who are stimulated with age-adjusted toys at an early age perform better in categories such as fine motor skills, understanding time and space, or cognitive abilities. The community-randomised trial conducted by the Swiss Tropical and Public Health Institute (Swiss TPH) and the Peruvian Instituto de Investigación Nutricional (IIN) is the first study to assess the impact of an early child development intervention on household level in rural Peru.
Medicine/Pharmacology
09.09.2016
New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions
NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions   Point of care in office diagnostics
Medicine/Pharmacology - Life Sciences
09.09.2016
Secrets of honey-making by bees unveiled
Bern, 09.09.2016 - From never seen before X-ray images of honey bee combs, a research team from Agroscope and the Institute of Bee Health at the University of Bern (both Switzerland) could study how honey is produced. The team used computer tomography to measure sugar concentration in the wax cells, without disturb-ing the sensitive mechanisms of the colony.
Computer Science/Telecom - Medicine/Pharmacology
08.09.2016
Alcon launches the NGENUITY 3D Visualization System designed to further enhance retinal surgeon experience
Heads-up design using high definition 3D screen engineered to improve surgeons posture and may reduce fatigue   Offers enhanced 3D visualization with high-definition resolution, image depth, clarity
Physics/Materials Science - Medicine/Pharmacology
08.09.2016
Affordable detectors for gamma radiation
A research team at Empa and ETH Zurich has developed single crystals made of lead halide perovskites, which are able to gage radioactive radiation with high precision. Initial experiments have shown that these crystals, which can be manufactured from aqueous solutions or low-priced solvents, work just as well as conventional cadmium telluride semi-conductors, which are considerably more complicated to produce.
Life Sciences - Medicine/Pharmacology
08.09.2016
Bacteria Supply Their Allies With Munitions
Bacteria Supply Their Allies With Munitions
Bacteria fight their competitors with molecular spear guns, the so-called Type VI secretion system. When firing this weapon they also unintentionally hit their own kind.
Business/Economics
07.09.2016
Industry meets science
Industry meets science
A record number of visitors attended this year's Industry Day. Around 550 representatives from industry and business met with scientists for a lively debate on the Hönggerberg.
Physics/Materials Science - Event
06.09.2016
Life Sciences - Physics/Materials Science
06.09.2016
Nanotechnology Supports Treatment of Malignant Melanoma
Nanotechnology Supports Treatment of Malignant Melanoma
Changes in the genetic make-up of tissue samples can be detected quickly and easily using a new method based on nanotechnology. This report researchers from the Swiss Nanoscience Institute, the University of Basel and the University Hospital Basel in first clinical tests with genetic mutations in patients with malignant melanoma.
Physics/Materials Science
06.09.2016
Exploding boules balls
A local festival, a pleasant summer's evening, a friendly game of boules - and suddenly a deafening bang.
Astronomy
05.09.2016
First gravitational waves form after 10 million years
This simulation shows how two galaxies merge over a period of 15 millionen years. The red and the blue dots illustrate the two black holes (image: Astrophysical Journal).
Medicine/Pharmacology
03.09.2016
Novartis’ Ultibro Breezhaler consistently more effective than Seretide * in reducing COPD flare-ups across different patient groups
Novartis' Ultibro Breezhaler consistently more effective than Seretide * in reducing COPD flare-ups across different patient groups Ultibro Breezhaler reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide in new analyses from FLAME study   Analyses show that Ultibro Breezhaler lowered patients' need for rescue medication and had improved benefit-risk profile compared to Seretide, with less evidence of systemic ef
Physics/Materials Science - Microtechnics/Electroengineering
02.09.2016
Michel Calame appointed new head of lab
The Reliability Science and Technology lab is set to focus on the topic of nanoscale transport phenomena and will have a new head, Michel Calame.
Medicine/Pharmacology - Life Sciences
01.09.2016
Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy
Phase III study showed Roche's cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy TECENTRIQ showed significant improvement in overall survival for people regardless of their PD-L1 status Data will be discussed with global health authorities, including the U.S.
Agronomy/Food Science - Business/Economics
01.09.2016
Nadja El Benni to head ‘Competitiveness and System Evaluation’ Research Division
Bern, 01.09.2016 - Dr. Nadja El Benni was appointed Head of the ‘Competitiveness and System Evaluation' Strategic Research Division by Agroscope Council on 25 August 2016.
Medicine/Pharmacology - Life Sciences
01.09.2016
X-ray View into Cerebellum
X-ray View into Cerebellum
Researchers at the University and University Hospital of Basel succeed in imaging microscopically small structures of the human brain in three dimensions and automatically detecting the number of Purkinje cells in this tissue. They report these results in the journal Scientific Reports. The human being consists of thousand times more cells than the Milky Way has stars.
Medicine/Pharmacology
31.08.2016
Medicine/Pharmacology
31.08.2016
AirFluSal Forspiro showed superiority at 12 months over Seretide Diskus [1] in persistence to treatment
New study shows that rate of patient persistence using Sandoz AirFluSal Forspiro is twice as high as for reference product Seretide Diskus.   Study highlights importance of improving treatment "persistence" over time for long-term respiratory diseases.   Analysis, published in leading medical journal, is largest European Real-World Evidence study ever conducted in asthma and COPD.